Login / Signup

A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib.

Chloe A LimNorbert BanyiTracy TuckerDiana N IonescuBarbara L Melosky
Published in: Current oncology (Toronto, Ont.) (2022)
We report a rare case of stage IV pulmonary combined large-cell neuroendocrine carcinoma (LCNEC) and adenocarcinoma (ACA), both demonstrating anaplastic lymphoma kinase ( ALK ) rearrangement by IHC and FISH. This 61-year-old lifelong nonsmoking Asian woman presented with a cough, and after diagnosis and surgical treatment, completed four cycles of adjuvant cisplatin and etoposide chemotherapy. She subsequently developed recurrence with bony metastases of exclusively ALK -positive LCNEC. Alectinib was started, and the patient experienced a partial response.
Keyphrases